611 W. Union Street
Benson, AZ 85602
(520) 586-0800

member support line
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line


611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line


powered by centersite dot net
Medical Disorders
Basic InformationLookupsLatest News
AHA News: Women May Be More Willing Than Men to Donate OrgansDNA Sensor Can Spot When COVID Is ContagiousTrials Show COVID Vaccines Well Worth It for Cancer PatientsCDC Endorses Booster Shots for Millions of AmericansChildhood Trauma Linked With Higher Odds for Adult Neurological IllsStudy Probes Relationship Between Migraines and SleepCancer in Hispanics: Good News and BadFDA Approves Pfizer Booster Shots for Seniors, High-Risk AmericansU.S. to Buy 500 Million More COVID Vaccine Doses for Global DonationAntibodies to Early Strains of COVID May Not Fight New Variants: StudyPregnant Women Who Get COVID Vaccine Pass Antibodies to NewbornsCDC Expert Panel to Weigh In on Vaccine BoostersWhich Kids Are at Highest Risk From COVID?4 Out of 10 Adults With No Known Heart Disease Have Fatty Hearts: StudyBooster Dose of J&J COVID Vaccine Increases ImmunityPost-Stroke Rehab: There's a Sweet Spot in the TimingCommon Form of Liver Cancer on the Rise in Rural AmericaCOVID Has Killed More Americans Than the Spanish Flu Did in 1918Telemedicine Gets High Marks for Follow-Ups After SurgeryPandemic Tied to Declining Birth Rates for U.S., Much of EuropeStudy Spots People at High Risk of Severe Breakthrough COVIDReview of Booster Shots for Moderna, J&J Vaccines Just Weeks Away: FauciDelta Variant Now Fueling 99% of U.S. COVID CasesLower Dose of Pfizer COVID Vaccine Works Well in Young Children, Company SaysFDA Panel OKs Pfizer Booster Shot for  People 65 or Older, But Not YoungerLong-Haul COVID in Kids Typically Ends Within 3 Months: StudyPfizer, Moderna Vaccines Still Offer Good Protection Against Severe COVID: StudyTrial Into Antioxidant for Parkinson's Disease Yields Disappointing ResultsIs Flu Ready for a Comeback? Get Your ShotCommon Eye Conditions Tied to Higher Risk for DementiaDrug Might Stop Heart Trouble Linked to Sickle Cell AnemiaChild Obesity Rose Sharply During PandemicFDA Advisory Panel to Meet on COVID Booster ShotsStatin Cholesterol Drugs May Help Fight Ulcerative ColitisAHA News: Physical Activity Is Helpful After a Stroke, But How Much Is Healthy?Special 'Strategies' Can Help People With Parkinson's Walk, But Many Patients UnawareEven When Undergoing Treatment, People With MS Gain From COVID VaccinesNIH Spending Nearly $470 Million on Long-Haul COVID StudyHospitalizing the Unvaccinated Has Cost U.S. Nearly $6 BillionIn 16 States, 35% or More Residents Now Obese: CDCPet Store Puppies Passing Drug-Resistant Bacteria to PeopleIs a Combo COVID/Flu Shot on the Way?1 in 500 Americans Has Died From COVID-19Having Even a Cousin or Grandparent With Colon Cancer Raises Your Risk: StudyBlood Cancer Patients Could Benefit From COVID Booster Shot: StudyWHO Says Africa Will Get 30% of COVID Vaccines It Needs by FebruaryCOVID Vaccines for Kids Under 12 Could Come This Fall: FauciEbola Vaccine Effective in African Clinical TrialBritain OK's COVID Vaccine for Kids 12 and Older; Hopes to Avoid LockdownsIsraeli Data on COVID Boosters to Be Published This Week in Major Journal
Questions and AnswersLinksBook Reviews
Related Topics

Men's Health
Women's Health

High Blood Pressure: Which Drug Works Best for You?

HealthDay News
by By Amy Norton HealthDay Reporter
Updated: Jul 27th 2021

new article illustration

TUESDAY, July 27, 2021 (HealthDay News) -- Two long used types of blood pressure drugs are equally effective, but the less popular one seems to have fewer side effects, according to a large "real-world" study.

The two classes of medication are both recommended as "first-line" treatments for high blood pressure: angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs).

ACE inhibitors have been around longer and studied more extensively, so doctors prescribe them more often.

But the new findings suggest that ARBs might be a better choice for people just starting on medication, the researchers said.

"There was no difference in the effectiveness of the drugs," senior researcher Dr. George Hripcsak said. "If you're not having side effects [with an ACE inhibitor], there's no need to switch."

Looking at data on nearly 3 million patients, the investigators found that ACE inhibitors and ARBs were equally effective at lowering the risks of heart disease and stroke.

Where they differed was side effects: ACE inhibitors were more likely to cause chronic cough and angioedema — severe swelling under the skin, often in the face.

People on ACE inhibitors were also slightly more likely to have gastrointestinal (GI) bleeding or inflammation of the pancreas. But those differences may have been due to chance, cautioned Hripcsak, a professor at Columbia University Vagelos College of Physicians and Surgeons, in New York City.

Going forward, he said, doctors might want to "preferentially" prescribe ARBs as a first treatment for high blood pressure. This class of drugs includes Losartan, Valsartan and Candesartan.

But people who are already using an ACE inhibitor and doing fine can stick with it. ACE inhibitors include lisinopril, captopril and fosinopril.

The study was published online July 26 in the journal Hypertension.

There is a long list of medications for high blood pressure, and guidelines recommend both ACE inhibitors and ARBs as first-line options. Both classes have been proven effective in lowering blood pressure and curbing the risks of heart disease and stroke.

But, Hripcsak said, few trials have made head-to-head comparisons of the two drug types to help doctors make decisions on which to prescribe.

So his team looked to real-world data. They used a few large databases from the United States, South Korea and Europe, with health records from nearly 3 million patients who were newly starting an ACE inhibitor or an ARB sometime between 1996 and 2018.

The large majority — almost 2.3 million — were prescribed an ACE inhibitor as their single blood pressure medication. The rest (almost 674,000) were started on an ARB.

Overall, the study found, there was no clear difference between the two groups in their average risk of suffering a heart attack, stroke or heart failure.

ACE inhibitor patients were, however, three times more likely to develop angioedema, and 32% more likely to develop a persistent cough, the findings showed.

The risks of GI bleeding and pancreatitis were also slightly higher among ACE inhibitor users. But those figures did not hold up to a statistical analysis the researchers performed, which means they could be chance findings.

Dr. Willie Lawrence is a cardiologist at the Center for Better Health, in Benton Harbor, Mich. He said that, in his experience, GI bleeding and pancreatitis have not been issues with the medications.

On the other hand, angioedema and "ACE cough" are well-known potential side effects, said Lawrence, who heads the American Heart Association's National Hypertension Control Initiative Oversight Committee.

There has already been a sense that ARBs are less likely to cause those problems, Lawrence said. But since ACE inhibitors have been available longer, doctors are inclined to prescribe them more often, he added.

"I think this study raises the question of whether it's better to just go straight to an ARB," Lawrence said.

But, he noted, the study does not provide a solid answer: There are inherent limits to observational studies such as this, which track patients given a particular treatment in the real world. Controlled clinical trials, which are designed to specifically test a treatment, offer better evidence.

However, it's unlikely anyone will conduct a trial pitting ACE inhibitors against ARBs, Lawrence said. Both drug classes are already widely used and available as inexpensive generics, so there's no incentive for drug makers to run expensive trials.

"I think patients should be aware that ACE inhibitors can cause cough and angioedema, and if you develop those symptoms, tell your primary care provider," Lawrence said.

But, like Hripcsak, he said that patients who are faring well with an ACE inhibitor have no reason to make a change.

More information

The American Heart Association has advice on managing high blood pressure.

SOURCES: George Hripcsak, MD, professor and chair, biomedical informatics, Columbia University Vagelos College of Physicians and Surgeons, New York City; Willie Lawrence, MD, head, National Hypertension Control Initiative Oversight Committee, American Heart Association, Dallas, and interventional cardiologist, Center for Better Health, Benton Harbor, Mich.; Hypertension, July 26, 2021, online